History
Liraglutide was the second GLP-1 receptor agonist on the US market, after exenatide. The FDA approved it as Victoza for type 2 diabetes on January 25, 2010. On December 23, 2014, the same molecule was approved at a higher dose as Saxenda, the first GLP-1 medicine approved for chronic weight management. Saxenda was approved for teenagers aged 12 to 17 on December 4, 2020.
Victoza gained a second use on August 25, 2017, when the FDA approved it to lower the risk of heart attack, stroke and heart death in adults with type 2 diabetes and heart disease. That approval was based on the LEADER trial. Victoza is also approved for children with type 2 diabetes aged 10 and older.
Mechanism and dosing
Liraglutide is a modified form of human GLP-1 with a fatty side chain that slows its breakdown. That gives it a half-life of about 13 hours, so liraglutide is injected once a day. Newer drugs such as semaglutide use a similar design but last about a week. The Saxenda label tops out at 3 mg a day and Victoza at 1.8 mg, reached step by step (see titration).
Clinical trials
Saxenda was approved based on the SCALE trial program. In the 56-week SCALE trial, people on liraglutide 3.0 mg lost 8.4 kg on average, vs. 2.8 kg on placebo. Later trials of weekly medicines such as semaglutide and tirzepatide reported larger average weight loss, and liraglutide is now prescribed less often for weight.
The most common side effects of liraglutide are nausea, diarrhea, constipation, vomiting and headache, mostly in the first weeks. Because it is a daily shot, some people find it harder to keep up with than a weekly one.
Generics
On December 23, 2024, the FDA approved the first generic liraglutide referencing Victoza, made by Hikma. More generic versions followed in 2025, and on August 27, 2025, the FDA approved the first generic referencing Saxenda. Liraglutide became the first GLP-1 medicine for weight management available as a generic. Like the brands, generic liraglutide carries a boxed warning about thyroid C-cell tumors seen in rodents.
A side-by-side view of liraglutide and the weekly options is on our medication comparison page.
Timeline
- 2010-01-25Victoza approved for type 2 diabetes
- 2014-12-23Saxenda approved for chronic weight management
- 2024-12-23First generic referencing Victoza approved
- 2025-08-27First generic referencing Saxenda approved
See also
References
- Victoza prescribing information, NDA 022341, FDA (2024). accessdata.fda.gov
- Pi-Sunyer et al., NEJM 2015 (SCALE Obesity and Prediabetes). pubmed.ncbi.nlm.nih.gov
- FDA approves first generic of once-daily GLP-1 injection (FDA, December 23, 2024). fda.gov
- GDUFA Performance Report to Congress FY 2025, FDA. fda.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.